The Utility of Hyperacetylated HMGB1 as Tumor Marker of Malignant Mesothelioma; a prospective observational study

The Utility of Hyperacetylated HMGB1 as Tumor Marker of Malignant Mesothelioma; a prospective observational study - The Utility of Hyperacetylated HMGB1 as Tumor Marker of Malignant Mesothelioma

Status

Active, not recruiting

Phases

Unknown

Study type

Observational

Source

JPRN

Registry ID

JPRN-UMIN000024455

Enrollment

100

Registered

2016-11-01

Start date

2016-11-01

Completion date

Unknown

Last updated

2026-06-29

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Malignant Mesothelioma

Interventions

None listed

Eligibility

Sex/Gender

All

Inclusion criteria

Inclusion criteria: 1. Pathologically diagnosed malignant mesothelioma patients. 2. Patients with pleural effusion, which is derived from malignant tumor other than malignant mesothelioma. 3. Patients with benign pleural effusion 4. Healthy volunteers

Exclusion criteria

Exclusion criteria: 1. Patients who refuse to participate in the study 2. Any patient found to be not applicable by an examiner

Design outcomes

Primary

Measure	Time frame
Ability of prognostic prediction and correlations with IMIG classification, existing tumor markers, and inflammatory factors of HMGB1 and its isoforms	—

Secondary

Measure	Time frame
Ability of prognosis prediction, correlations with IMIG classification, existing tumor markers, and inflammatory factors	—

Countries

Japan,North America

Contacts

Public ContactRyota Ushio / Masaharu Shinkai

Yokohama City University Graduate School of Medicine Department of Pulmonology

rushio@yokohama-cu.ac.jp045-787-2508

Outcome results